Search tips
Search criteria 


Logo of pharmscispringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSci. 2004 March; 6(1): 68–76.
Published online 2015 July 10. doi:  10.1208/ps060107
PMCID: PMC2750942

β-cyclodextrin complexes of celecoxib: Molecular-modeling, characterization, and dissolution studies


Celecoxib, a specific inhibitor of cycloxygenase-2 (COX-2) is a poorly water-soluble nonsteroidal anti-inflammatory drug with relatively low bioavailability. The effect of β-cyclodextrin on the aqueous solubility and dissolution rate of celecoxib was investigated. The possibility of molecular arrangement of inclusion complexes of celecoxib and β-cyclodextrin were studied using molecular modeling and structural designing. The results offer a better correlation in terms of orientation of celecoxib inside the cyclodextrin cavity. Phase-solubility profile indicated that the solubility of celecoxib was significantly increased in the presence of β-cyclodextrin and was classified as AL-type, indicating the 1[ratio]1 stoichiometric inclusion complexes. Solid complexes prepared by freeze drying, evaporation, and kneading methods were characterized using differential scanning calorimetry, powder x-ray diffractometry, and scanning electron microscopy. In vitro studies showed that the solubility and dissolution rate of celecoxib were significantly improved by complexation with β-cyclodextrin with respect to the drug alone. In contrast, freeze-dried complexes showed higher dissolution rate than the other complexes.

Keywords: celecoxib, β-cyclodextrin, complexation, molecular-modeling, phase solubility, characterization, dissolution rate


1. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib. Clin Pharmacokinet. 2000;38:225–242. doi: 10.2165/00003088-200038030-00003. [PubMed] [Cross Ref]
2. Simon LS, Lanza FL, Lipsky PE. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum. 1998;41:1591–1602. doi: 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J. [PubMed] [Cross Ref]
3. Hubbard RC, Koepp RJ, Yu S. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study [abstract] Arthritis Rheum. 1996;39:226–226. doi: 10.1002/art.1780390208. [PubMed] [Cross Ref]
4. Hubbard RC, Mehlisch DR, Jasper DR. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model [Abstract]. J Invest Med. 1996;44: Abstract 293.
5. Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001;297:638–645. [PubMed]
6. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442. doi: 10.1056/NEJM200108093450607. [PubMed] [Cross Ref]
7. Szejtli J. Cyclodextrin Technology. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1988. pp. 81–83.
8. Loftson T, Brewster ME. Pharmaceutical applications of cyclodextrins: 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017–1025. doi: 10.1021/js950534b. [PubMed] [Cross Ref]
9. Connors KA. The stability of cyclodextrin complexes in solution. Chem Rev. 1997;97:1325–1357. doi: 10.1021/cr960371r. [PubMed] [Cross Ref]
10. Uekema K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045–2076. doi: 10.1021/cr970025p. [PubMed] [Cross Ref]
11. Stella VJ, Rajiwski RA. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res. 1997;14:556–567. doi: 10.1023/A:1012136608249. [PubMed] [Cross Ref]
12. Uekama K, Hirayama F. Methods of investigating and preparing inclusion compounds. In: Duchene D, editor. Cyclodextrins and Their Industrial Uses. Paris, France: Editions de Santé; 1987. pp. 131–172.
13. Erden N, Celebi N. A study of the inclusion complex of naproxen with β-cyclodextrin. Int J Pharm. 1988;48:83–89. doi: 10.1016/0378-5173(88)90250-5. [Cross Ref]
14. Pop MM, Goubitz K, Borodi G, Bogdan M, De Ridder DJ, Peschar R, Schenk H. Crystal structure of the inclusion complex of betacyclodextrin with mefenamic acid from high-resolution synchrotron powder-diffraction data in combination with molecular-mechanics calculations. Acta Crystallogr B. 2002;58:1036–1043. doi: 10.1107/S010876810201947X. [PubMed] [Cross Ref]
15. Bonmet P, Jaime C, Morin-Allory L. Alpha-, beta-, and gamma-Cyclodextrin dimers: Molecular modeling studies by molecular mechanics and molecular dynamics simulations. J Org Chem. 2001;66:689–692. doi: 10.1021/jo0008284. [PubMed] [Cross Ref]
16. Ding HO, Karasawa N, Goddard WA. Atomic level simulations on a million particles: The cell multipole method for Coulomb and London nonbond interactions. J Chem Physiol. 1992;97(6):4309–4315. doi: 10.1063/1.463935. [Cross Ref]
17. Swope WC, Andersen HC. A computer simulation method for the calculation of equilibrium constants for the formation of physical clusters of molecules: Application to small water clusters. J Chem Physiol. 1982;76(1):637–649. doi: 10.1063/1.442716. [Cross Ref]
18. Higuchi T, Connors KA. Phase solubility diagram. Adv Anal Chem Instrum. 1965;4:117–212.
19. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48–49. doi: 10.1111/j.2042-7158.1975.tb09378.x. [PubMed] [Cross Ref]
20. Furlanetto S, Maestrelli F, Orlandini S, Pinzauti S, Mura P. Optimization of dissolution test precision for a ketoprofen oral extended-release product. J Pharm Biomed Anal. 2003;32:159–165. doi: 10.1016/S0731-7085(03)00032-3. [PubMed] [Cross Ref]
21. Marques CH, Hadgraft J, Kellaway I. Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int J Pharm. 1990;63:259–266. doi: 10.1016/0378-5173(90)90132-N. [Cross Ref]
22. Uekama K, Hirayama F. Improvement of drug properties by cyclodextrin. In: Wermuth CG, editor. The Practice of Medicinal Chemistry. London, UK: Academic Press; 1996. pp. 793–825.
23. Szetli J. Medicinal applications of cyclodextrins. Med Res Rev. 1994;14:353–386. doi: 10.1002/med.2610140304. [PubMed] [Cross Ref]
24. Trapani G, Latrofa A, Franco M, et al. Complexation of Zolpiden with 2-hydroxypropyl-b-, methyl-b-, and 2-hydroxypropyl-g-cyclodextrin: Effect on aqueous solubility, dissolution rate and ataxic activity in rat. J Pharm Sci. 2000;89:1443–1451. doi: 10.1002/1520-6017(200011)89:11<1443::AID-JPS7>3.0.CO;2-Q. [PubMed] [Cross Ref]

Articles from AAPS PharmSci are provided here courtesy of American Association of Pharmaceutical Scientists